| P50 | author | Paolo Navalesi | Q40672716 |
| | Alessandro Vatrella | Q48541083 |
| | Rosa Terracciano | Q55080364 |
| | Girolamo Pelaia | Q87123110 |
| | Luca Gallelli | Q88962280 |
| | Corrado Pelaia | Q94456854 |
| P2093 | author name string | Rosario Maselli | |
| P2860 | cites work | Th2 cytokines and asthma. Interleukin-4: its role in the pathogenesis of asthma, and targeting it for asthma treatment with interleukin-4 receptor antagonists | Q24791820 |
| | Role of biologics in severe eosinophilic asthma - focus on reslizumab | Q26738503 |
| | A summary of the new GINA strategy: a roadmap to asthma control | Q26799984 |
| | IL-4 and IL-13 signaling in allergic airway disease | Q26859510 |
| | Update on anticytokine treatment for asthma | Q27013617 |
| | Development of New Therapies for Severe Asthma | Q28077546 |
| | Biologics in asthma--the next step toward personalized treatment | Q28085614 |
| | Asthma | Q28237297 |
| | Interleukin-13: central mediator of allergic asthma | Q28291712 |
| | The global burden of asthma: executive summary of the GINA Dissemination Committee report | Q29614904 |
| | Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions | Q33669033 |
| | Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy | Q33713754 |
| | Evolving Concepts of Asthma | Q33735605 |
| | Lebrikizumab treatment in adults with asthma | Q34205683 |
| | Targeting interleukin-4 in asthma: lost in translation? | Q34271232 |
| | Interleukin-4 receptor signaling pathways in asthma pathogenesis | Q34355560 |
| | Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma | Q34624473 |
| | Influence of comorbid conditions on asthma | Q34972370 |
| | Predictors of therapy resistant asthma: outcome of a systematic evaluation protocol | Q35536031 |
| | Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis | Q36660614 |
| | Serum periostin in obstructive airways disease | Q36854205 |
| | Immunological decision-making: how does the immune system decide to mount a helper T-cell response? | Q36993451 |
| | Current concepts of severe asthma | Q37042266 |
| | Type I IL-4Rs selectively activate IRS-2 to induce target gene expression in macrophages. | Q37337400 |
| | Untangling the complex web of IL-4- and IL-13-mediated signaling pathways | Q37358425 |
| | Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma | Q37360189 |
| | A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. | Q37397800 |
| | Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis | Q37709681 |
| | Increased sputum and bronchial biopsy IL-13 expression in severe asthma | Q37711413 |
| | The potential of biologics for the treatment of asthma | Q38063791 |
| | 'All things considered': transcriptional regulation of T helper type 2 cell differentiation from precursor to effector activation | Q38106128 |
| | Role of interleukin-13 in asthma | Q38136542 |
| | International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma | Q38171268 |
| | GATA-3 function in innate and adaptive immunity. | Q38242235 |
| | Dupilumab: a novel treatment for asthma | Q38248590 |
| | Emerging molecular phenotypes of asthma | Q38261186 |
| | The paradigm of cytokine networks in allergic airway inflammation | Q38283796 |
| | Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis: A Randomized Clinical Trial | Q38396364 |
| | Type 2 cytokines: mechanisms and therapeutic strategies | Q38424752 |
| | Targeting key proximal drivers of type 2 inflammation in disease | Q38608260 |
| | Asthma phenotypes and IgE responses | Q38671986 |
| | Targeted therapy in severe asthma today: focus on immunoglobulin E. | Q38673097 |
| | Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy. | Q38733745 |
| | Human circulating group 2 innate lymphoid cells can express CD154 and promote IgE production | Q38749002 |
| | Interleukin-4 receptor signaling and its binding mechanism: A therapeutic insight from inhibitors tool box. | Q38831470 |
| | Dupilumab for the treatment of asthma | Q39022174 |
| | Commonality of the IL-4/IL-13 pathway in atopic diseases | Q39170851 |
| | Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4Rα, in Atopic Dermatitis Patients and Normal Volunteers. | Q39251816 |
| | Dupilumab: First Global Approval | Q39331951 |
| | New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait! | Q39352939 |
| | Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial | Q40445632 |
| | Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. | Q40672713 |
| | Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial | Q40693199 |
| | Reconstitution of a functional human type II IL-4/IL-13 receptor in mouse B cells: demonstration of species specificity | Q40830754 |
| | Suppressor of Cytokine Signaling (SOCS)1 Regulates Interleukin-4 (IL-4)-activated Insulin Receptor Substrate (IRS)-2 Tyrosine Phosphorylation in Monocytes and Macrophages via the Proteasome | Q41161742 |
| | Commentary: IL-4 and IL-13 receptors and signaling | Q41818218 |
| | Requirement for IL-13 independently of IL-4 in experimental asthma | Q41881960 |
| | Dupilumab in persistent asthma with elevated eosinophil levels | Q44480181 |
| | Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study | Q44980719 |
| | Asthma and corticosteroids: time for a more precise approach to treatment | Q46072029 |
| | Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids | Q46278976 |
| | Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis | Q47651802 |
| | Asthma severity and medical resource utilisation | Q47973722 |
| | Asthma: still a promising future? | Q48693496 |
| | IL-13 receptor alpha2 selectively inhibits IL-13-induced responses in the murine lung | Q50232098 |
| | Costs of asthma according to the degree of severity. | Q50637174 |
| | Inhibiting interleukin-4 and interleukin-13 in difficult-to-control asthma. | Q50979608 |
| | Interleukin-13-induced activation of signal transducer and activator of transcription 6 is mediated by an activation of Janus kinase 1 in cultured human bronchial smooth muscle cells. | Q54506973 |
| | Increased Expression of Plasma and CD4+ T Lymphocyte Costimulatory Molecule CD26 in Adult Patients with Allergic Asthma | Q59314259 |
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | asthma | Q35869 |
| P304 | page(s) | 1565-1572 | |
| P577 | publication date | 2017-10-08 | |
| P1433 | published in | Expert Opinion on Biological Therapy | Q5421201 |
| P1476 | title | Dupilumab for the treatment of asthma | |
| P478 | volume | 17 | |